Welcome to our dedicated page for CIBUS SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cibus, Inc. (Nasdaq: CBUS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Cibus’ operations as an agricultural technology company that develops and licenses gene-edited plant traits to seed companies.
Through its recent Forms 8-K, Cibus has reported a range of material events, such as quarterly financial results and business updates, workforce reduction decisions, and the appointment of key executives and directors. For example, filings describe the appointment of a Chief Financial Officer under an executive employment agreement, the election of new board members with experience in technology, agriculture and finance, and actions to streamline the business by consolidating facilities and reducing headcount.
These filings also confirm that Cibus’ Class A common stock, with par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol CBUS. Investors reviewing the filings can see how the company describes its focus on productivity traits for major row crops, its reliance on licensing and royalty arrangements, and its assessment of risks and strategic alternatives as referenced in its periodic reports.
On Stock Titan, Cibus filings are supplemented with AI-powered summaries that help explain the key points of lengthy documents, such as current reports on Form 8-K or sections of annual and quarterly reports. Users can quickly identify items related to executive changes, cost structure adjustments, or updates to trait development programs, and then drill down into the full text for more detail. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track CBUS regulatory disclosures, including insider-related items reported on Form 4 and the narrative and risk discussions contained in Forms 10-K and 10-Q.
Cibus, Inc. reported its results for the three months ended September 30, 2025 and provided a year‑to‑date business update. The company furnished a press release with details as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under the Exchange Act, limiting its use for liability purposes unless specifically incorporated by reference. The report was signed by Interim Chief Executive Officer Peter Beetham on November 13, 2025.
Cibus, Inc. (CBUS) appointed Craig Wichner to its Board of Directors, effective November 5, 2025, and named him to the Board’s Strategy Committee.
Wichner is the Founder and Managing Partner of Farmland LP, a U.S. farmland investment manager with more than $350 million in assets and over 19,000 acres under management. His annual director compensation includes a $60,000 cash retainer (payable semi-annually) and equity with a grant date value of $90,000, prorated for the remainder of fiscal 2025, subject to Board approval under the company’s 2017 Omnibus Incentive Plan. He also entered into the company’s standard indemnification agreement.
Kimberly A. Box, a director of Cibus, Inc. (CBUS), was granted a stock option on 09/11/2025 to purchase 54,722 shares of Class A common stock at an exercise price of $1.40 per share. The option vests on the earlier of the first anniversary of the grant date or the company’s next annual shareholders meeting, subject to continued service, and becomes exercisable beginning 09/11/2026 with an expiration date of 09/11/2035. The filing reports direct beneficial ownership of 54,722 shares following the grant. The grant includes standard acceleration on a defined Triggering Event per the company’s 2017 Omnibus Incentive Plan.
Cibus, Inc. (CBUS) Form 3 filed by Kimberly A. Box discloses her role as a director and reports zero shares of Class A common stock and no derivative securities as of the 09/11/2025 event date. The filing is an initial beneficial-ownership statement and was signed by an attorney-in-fact on 09/26/2025. The disclosure documents the absence of direct equity holdings by this reporting director.
Cibus, Inc. disclosed an Executive Employment Agreement appointing Cornelis (Carlo) Broos as Chief Financial Officer effective
Cibus, Inc. notified the appointment and compensation terms for non-employee director Ms. Box. The Board adopted a Non-Employee Director Compensation Policy providing Ms. Box an annual cash retainer of $60,000 payable semi-annually and equity compensation with a grant-date value of $90,000 to be issued under the Cibus, Inc. 2017 Omnibus Incentive Plan, as amended. The award will be prorated to reflect Ms. Box's service for the remainder of the 2025 fiscal year. The filing is signed by Peter Beetham, Ph.D., Interim Chief Executive Officer.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,540,536 shares of Cibus, Inc. Class A common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises shared voting and dispositive power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported to share voting and dispositive power. The Master Fund disclaims direct beneficial ownership by reason of the management agreement. The filing states the holdings are owned in the ordinary course of business and not for the purpose of changing or influencing control.
Cibus, Inc. reported continued losses and liquidity pressure while narrowing its operational focus to commercialize rice herbicide-tolerance traits. The company recorded a $76.0 million net loss for the six months ended June 30, 2025, and used $25.4 million of cash in operating activities during that period. Cash and cash equivalents were $36.5 million versus current liabilities of $22.4 million, and an accumulated deficit of $803.4 million. Management expects to continue incurring losses and needs additional capital within a year; this raises substantial doubt about the companys ability to continue as a going concern. Cibus implemented cost reductions and a restructuring, targets annual net cash usage of approximately $30.0 million by 2026, and is prioritizing Rice weed-management traits that it estimates could represent >$200 million of annual accessible royalties upon full commercialization. The company recognized a $21.0 million goodwill impairment in Q1 2025 and completed equity transactions in Jan and Jun 2025 to raise net proceeds of about $46.4 million combined.
Cibus, Inc. submitted a current report describing that it has announced its financial results for the three months ended June 30, 2025 and provided a year-to-date business update. These results and the business update are contained in a press release dated August 14, 2025, which is furnished as Exhibit 99.1.
The company clarifies that this press release is being furnished, not filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Cibus by Interim Chief Executive Officer Peter Beetham.